900 STEWART AVENUE, GARDEN CITY, NY
Announces Exercise of Warrants for $3.25 Million of Gross Proceeds
Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults
Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
News, Articles of Incorporation
Shareholder votes
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy
Changes in Board, Management or Compensation, Other Events
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
Confidential Treatment Order